EU Panel Backs Expanding Ribociclib Approval in HR+/HER2- Breast Cancer

November 16, 2018 – The European Medicine’s Agency Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the approval of ribociclib in women with HR+/HER2-negative breast cancer to include use in combination with fulvestrant as initial endocrine-based therapy, as well as for women who received prior endocrine therapy. Ribociclib was also recommended to be approved in combination with endocrine therapy and an … (leggi tutto)